The therapeutic effect of Sildenafil Citrate on maternal and fetal outcomes of pregnancies associated with severe preeclampsia
Phase 3
Recruiting
- Conditions
- Severe Preeclampsia.Severe pre-eclampsia
- Registration Number
- IRCT20190201042577N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 64
Inclusion Criteria
Pregnant women with single pregnancy with gestational age 24 to 34 weeks
Ladies 18 to 50 years old
Patients with the diagnosis of severe preeclampsia (systolic blood pressure greater than 160 and diastolic blood pressure greater than 110 in two times with a minimum measurement time of 4 hours and proteinuria greater than 300 mg in 24 hours) indicating an expected treatment.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The mean of the pregnancy period since the diagnosis of severe preeclampsia until the end of pregnancy. Timepoint: since the diagnosis of severe preeclampsia until the end of pregnancy. Method of measurement: day.
- Secondary Outcome Measures
Name Time Method Mean maternal blood pressure. Timepoint: Every four hours. Method of measurement: mercury Barometer.;Newborn birth weight. Timepoint: at birth. Method of measurement: scaler.